<DOC>
	<DOC>NCT01719003</DOC>
	<brief_summary>This study will investigate the efficacy and safety of two doses (high and low) of empagliflozin in combination with metformin (500 mg and 1000 mg) administered twice daily in patients with type 2 diabetes mellitus (T2DM). Study will compare four dose combinations of empagliflozin + metformin versus each individual component after 24 weeks of treatment.</brief_summary>
	<brief_title>Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Hyperglycemia</mesh_term>
	<mesh_term>Empagliflozin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Inclusion criteria: 1. Diagnosis of type 2 diabetes mellitus prior to informed consent 2. Male and female patients on diet and exercise regimen who are drugnaive, defined as absence of any oral antidiabetic therapy for 12 weeks prior to randomization 3. HbA1c &gt;=7.5% and &lt;= 12% (&gt;=58.5 mmol/mol and &lt;=107.7 mmol/mol) 4. Body Mass Index (BMI) &lt;= 45 kg/m2 at screening Exclusion criteria: 1. Uncontrolled hyperglycemia with a glucose level &gt;240 mg/dl (&gt;13.3 mmol/L) after an overnight fast during placebo runin and confirmed by a second laboratory measurement (not on the same day) 2. Any antidiabetic drug within 12 weeks prior to randomization 3. Impaired renal function, defined as estimated creatinine clearance rate (eCCr) &lt;60 ml/min (CockcroftGault formula) as determined during screening and/or runin period 4. Contraindications to metformin according to the local label</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>